Risk factorsBy Mayo Clinic Staff
Your risk of LCIS may be increased if:
Aug. 15, 2014
- You have a family history of breast cancer. If one or more close relatives have been diagnosed with breast cancer, you may have an increased risk of LCIS.
- You've taken hormone replacement therapy for menopause. Women who have used hormone replacement therapy for more than three to five years to help cope with menopausal signs and symptoms may have an increased risk of LCIS.
- You're a woman in your early 40s. Though LCIS is uncommon, it's most likely to be detected in women in their early 40s who haven't yet experienced menopause. However, LCIS is becoming more common in older women who have undergone menopause.
- Niederhuber JE, et al., eds. Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Breast cancer. Fort Washington, Pa.: National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed Feb. 17, 2014.
- Sabel MS. Atypia and lobular carcinoma in situ: High risk lesions of the breast. http://www.uptodate.com/home. Accessed March 12, 2014.
- Cameron JL, et al., eds. Current Surgical Therapy. 11th ed. Philadelphia, Pa.: Saunders Elsevier; 2014. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Chen WY. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention. http://www.uptodate.com/home. Accessed March 12, 2014.
- SEER stat fact sheet: Breast cancer. National Cancer Institute. http://seer.cancer.gov/statfacts/html/breast.html. Accessed March 12, 2014.
- Moyer VA. Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine. Sept. 24, 2013. http://annals.org/article.aspx?articleid=1740758. Accessed March 12, 2014.
- Visvanathan K, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2013;31:2942.
- Degnim AC, et al. Surgical management of high-risk breast lesions. Surgical Clinics of North America. 2013;93:329.
- Townsend CM Jr, et al. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 19th ed. Philadelphia, Pa.: Saunders Elsevier; 2012. http://www.clinicalkey.com. Accessed Feb. 17, 2014.
- Pruthi S (expert opinion). Mayo Clinic, Rochester, Minn. March 16, 2014.
- Vogel VG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727.